Form 4: Elevation Oncology Director Alan B. Sandler Acquires 35,000 Stock Options

Director Alan B. Sandler acquired 35,000 stock options in Elevation Oncology, Inc. on June 13, 2024.

Summary

• On June 13, 2024, Alan B. Sandler, a director of Elevation Oncology, Inc., acquired 35,000 stock options.
• The exercise price of these options is $3.35.
• The options vest 100% on the one-year anniversary of the grant date, contingent on continued service to the Issuer.
• The expiration date for these options is June 12, 2034.
• Following the transaction, Sandler directly owns 35,000 derivative securities.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing the acquisition of stock options by a company director. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Positives

• The acquisition of stock options by a director may indicate confidence in the company's future performance.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.

Stakeholder Impact

• The acquisition of stock options by a director could be viewed positively by shareholders, as it aligns the director's interests with the company's success.

Key Dates